Lentivirus-mediated MDA7/IL24 expression inhibits the proliferation of hepatocellular carcinoma cells

CHAO MA, LING-LING ZHAO, HENG-JUN ZHAO, JIU-WEI CUI, WEI LI and NAN-YA WANG

Oncology Center, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Received April 26, 2017; Accepted January 23, 2018

DOI: 10.3892/mmr.2018.8616

Abstract. MDA7/IL24 is a member of the IL-10 gene family that functions as a cytokine. Notably, supra-physiological endogenous MDA7 levels have been indicated to suppress tumor growth and induce apoptosis in different cancer types. In the present study, MDA7 roles were investigated during the proliferation of hepatocellular carcinoma (HCC) cells and the molecular mechanisms underlying this process. A lentiviral vector expressing MDA7/IL24 (LV-MDA7/IL24) was constructed and used to infect HCC SMMC-7721 cells. The expression levels of MDA7/IL24 in these cells were determined using RT-qPCR and western blot analysis. The effects of LV-MDA7/IL24 on cell proliferation were analyzed using MTT and colony formation assays. Furthermore, the influence of LV-MDA7/IL24 on cell apoptosis and cell cycle distribution were detected using flow cytometry. The underlying molecular mechanisms were investigated using microarray and western blot analysis. The expression of MDA7/IL24 was confirmed to be significantly increased in the cells infected with LV-MDA7/IL24 compared with that of the negative-control infected group. Lentivirus-mediated MDA7/IL24 expression was found to inhibit HCC cell proliferation and colony formation, and it also induced cell arrest and apoptosis. Microarray analysis and western blotting results indicated that multiple cancer-associated pathways and oncogenes are regulated by MDA7/IL24, including cell cycle regulatory and apoptosis activation pathway. In conclusion, it was determined that MDA7/IL24 inhibits the proliferation and reduces the tumorigenicity of HCC cells by regulating cell cycle progression and inducing apoptosis, indicating that it may be used as a potential prognostic and therapeutic target in HCC.

Introduction

Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third leading cause of cancer-related death worldwide. Despite the development of various therapies, the outcome for HCC patients remains poor. Generally, HCC patients have a 1-year survival rate of <50% and a 5-year survival rate of 10% (1). Annually, ~0.11 million people die from liver cancer in China, and the major reason for frequent HCC relapses are intrahepatic and distant metastases that develop after the curative surgical resection or transplantation (2). Moreover, HCC is insensitive to chemotherapy and radiotherapy (3). Therefore, novel HCC treatments such as gene therapy and molecular targeted therapy should be investigated (4). As a multitarget anticancer drug, sorafenib has been approved for the treatment of HCC, but showed a very low success rate (5). Gene therapy represents an alternative form of cancer treatment and was shown to have high efficiency, specificity, and few serious side effects (4).

Melanoma differentiation-associated gene7/interleukin-24 (MDA7/IL24), a member of the IL10 cytokine family, was originally identified as a gene associated with the terminal differentiation and irreversible growth suppression of metastatic human melanoma cells (6). MDA7/IL24 is considered to be secreted by the immune system and melanocytes alone (7,8). Several reports demonstrated the loss of MDA7/IL24 expression during the progression of melanoma, and a significant inverse correlation between the loss of this gene and tumor invasion, suggesting that MDA7/IL24 may have anticancer effects (6,7,9,10). Additionally, our previous studies demonstrated that MDA7/IL24 has multiple anticancer functions, selectively inducing cancer cell apoptosis, but also showing immunomodulatory and antiangiogenic properties and strong antitumor bystander effects, which makes this molecule an ideal candidate for cancer gene therapy (9-13).

We constructed MDA7/IL24-expressing lentiviral particles, and evaluated the effects of lentivirus-mediated MDA7/IL24 expression on HCC cell proliferation and colony-forming ability. Moreover, we explored the mechanisms underlying MDA7/IL24-mediated HCC regression (14).

Materials and methods

Cell lines and culture conditions. HCC cell line SMMC-7721 was obtained from Cell Bank of Chinese Academy of Sciences.
(Shanghai, China), and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 100 U/ml of penicillin-streptomycin. The cells were incubated at 37°C in a humidified atmosphere with 5% CO₂. In addition, the cell line is not contaminated or mis-identified according to the Database of Cross-Contaminated or Misidentified Cell Lines.

Recombinant lentiviral particle construction and infection. We constructed MDA7/IL24 gene expression plasmid, while an empty plasmid was used as a negative control. Following this, MDA7/IL24-expressing plasmid or the negative control plasmid, together with pHelper 1.0 and pHelper 2.0 (pVSVG-I and pCMVAR 8.92 plasmids, respectively), were added to 293T cells with Lipofectamine 2000 (Invitrogen, Shanghai, China), according to the manufacturer's instructions. After 48 h of transfection, supernatants containing viral particles were collected and centrifuged (1,006 g, 20 min) to get rid of cell debris, and filtered through 0.45-µm polyvinylidene fluoride (PVDF) membranes. HCC cells were infected with MDA7/IL24-expressing lentiviral particles or the controls at the multiplicity of infection (MOI) of 20. The infected cells expressing green fluorescent protein (GFP) were observed under a fluorescence microscope (Micro Publisher 3.3RTV; Olympus, Tokyo, Japan). The cells were collected and total RNA was extracted to determine the efficiency of knockdown.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was extracted and purified from SMMC-7721-infected cells, using Trizol reagent (Invitrogen) following the manufacturer's instructions. RT was performed to generate cDNA molecules, using M-MLV reverse transcriptase (Promega, Madison, WI, USA) and oligo(dT) primers (Sangon, Shanghai, China), following the manufacturers' instructions. The expression of MDA7/IL24 was determined by quantitative real-time (qRT)-PCR, using a PCR assay kit (TransGen Biotech, Beijing, China). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA was amplified as an internal reference. MDA7/IL24 primer set: Forward, 5'-TTGCTCTGGTTTACCTGC-3' and reverse, 5'-AAGCCTTCCACAGTTCTGG-3'; GAPDH forward, 5'-TGAATTCACACGAGCACC-3' and reverse, 5'-CAC CCTGTCTGCTGGCCTAAA-3'. PCR conditions included initial denaturation (95°C for 10 sec) and then 40 cycles of amplification (95°C for 15 sec and 55°C for 15 sec). MDA7/IL24 relative expression was normalized to GAPDH levels by the 2^−ΔΔCt method (15).

MTT assay. To investigate the effects of MDA7/IL24 over-expression on cell viability, MTT assay was performed three times. SMMC-772 cells in the logarithmic growth phase were cultured for 24 h in 96-well plates (1x10⁵ cells per well). After the infection, cells were incubated for additional 72 h. Mitochondrial function was evaluated by MTT colorimetric assay. Briefly, the medium was removed and a fresh medium containing 0.5 mg/ml MTT was added to each well. The cells were incubated at 37°C for 4 h. Following this, the supernatants were removed, 50 µl dimethylsulfoxide (DMSO) was added to each well, and samples were incubated for 30 min at 37°C with gentle shaking. Finally, absorbance was determined using a microplate reader at 490 nm. Cell viability was calculated as the ratio of the absorbance determined in the samples infected with the MDA7/IL24 overexpression plasmid to that of the control group (untreated cells).

Colonization formation assay. Infected and untreated SMMC-7721 cells were plated in six-well plates (200 cells/well) and cultured in a 5% CO₂ incubator at 37°C for 14 days. The cells were washed twice with PBS and fixed in 4% paraformaldehyde for 30 min. Cell colonies were stained with Giemsa dye (Chemicon, Temecula, CA, USA) for 20 min, and washed with double distilled water several times. Colony numbers were counted under a fluorescence microscope.

Cell cycle. Cells were cultured in 12-cell plates. After 5 days, the cells were collected and fixed with cold 70% ethanol overnight at -20°C, and then washed with cold PBS for one time. The fixed cells were treated with RNase and stained with propidium iodide (Sigma, St. Louis, MO, USA). The stained cells were analyzed by flow cytometer and ModFit LT software (Verity Software House, Topsham, ME, USA).

Cell apoptosis. Cell apoptosis was performed using Annexin V PE and 7-AAD apoptosis detection kit (BD Bioscience, San Diego, CA, USA) according to the manufacturer's instructions. Cells were collected after cultured 5 days, washed and resuspended with 1xbinding buffer. Then 5 µl Annexin V was added into 200 µl of the above cell suspension and incubated at room temperature in the dark for 15 min. After incubation, 5 µl 7-AAD was added the cell apoptosis was detected using the flow cytometer.

Microarray processing and analysis. Total RNA isolated from SMMC-7721 cells infected with either lentiviral vector expressing (LV)-MDA7/IL24 (n=3) or negative control lentivirus (n=3) was subjected to microarray analysis, to determine the global transcriptomic profile of each cell group, using Affymetrix human GeneChip according to the manufacturer's instructions. Microarray hybridization, washing, and staining were performed using the GeneChip Hybridization Wash and Stain kit (Affymetrix, Santa Clara, CA, USA). Arrays were then scanned using the GeneChip Scanner 3,000 to obtain raw data (Affymetrix). Significant differences in the expression of the analyzed genes between SMMC-7721 cells infected with either LV-MDA7/IL24 or negative control lentivirus were obtained based on P<0.05.

Western blot analysis. Seventy-two h after the infection of SMMC-7721 cells with either LV-MDA7/IL24 or negative control lentivirus, the cells were collected and washed with PBS twice, and the lysis buffer was added to extract the cellular proteins. Afterwards, the lysates were centrifuged at 14,000 rpm at 4°C for 10 min and the supernatants were collected. BCA method was used to determine the protein concentration. Twenty micrograms of protein sample obtained from the infected cells was separated by 10% SDS-PAGE and then transferred to PVDF membrane. PVDF membranes were blocked at 4°C overnight with 5% bovine serum albumin and incubated with monoclonal antibodies against...
B cell lymphoma protein-2 (BCL2; 1:500; ab692; Abcam, Cambridge, UK), Cyclin E (1:1,000; cat. no. 4132), p-ERK1/2 (1:800; cat. no. 4370), p-AKT (1:2,000; cat. no. 4060) and caspase-3 (1:1,000; cat. no. 9662; all CST Biological Reagents Co., Ltd., Shanghai, China). Thereafter, the horseradish peroxidase-conjugated secondary antibody we added for each corresponding primary antibody. The obtained blots were analyzed using enhanced chemiluminescence. GAPDH was detected on the same membrane as a loading control.

Statistical analysis. Student’s t-test was performed for data analysis. Statistical analysis was performed using the SPSS version 22.0 software (SPSS, Chicago, IL, USA). All data were presented as mean ± standard deviation (SD) of the results obtained in three independent experiments. P<0.05 was considered to indicate a statistically significant difference.

Results

LV-MDA7/IL24 infection induces MDA7/IL24 overexpression in SMMC-7721 cells. As presented in Fig. 1A, SMMC-7721 cells were shown to be GFP-positive following the infection with the lentiviral particles, indicating a high efficiency of the infection. Further analysis demonstrated a significant upregulation of MDA7/IL24 expression in these cells (P<0.001), compared with that in the cells infected with the negative control lentiviruses (Figs. 1B and 2).
Figure 3. MDA7/IL24 overexpression suppresses SMMC-7721 cell proliferation. (A) Cell proliferation of LV-MDA7/IL24-infected cell, negative control-infected cells, and untreated cells. (B and C) The photomicrographs of SMMC-7721 cells at different time points, including the fluorescent images of experimental group cells and the bright-field images of the control group cells. Magnification, x100. OE, cells infected with LV-MDA7/IL24; NC, cells infected with the negative control particles; CON, untreated cells.
MDA7/IL24 overexpression inhibits SMMC-7721 cell proliferation and colony-forming ability. LV-MDA7/IL24-infected SMMC-7721 cells were shown to have a decreased growth rate, in comparison with the untreated and negative control-treated cells (P<0.05). At day 5, we determined that the optical density at 490 nm (OD490) of LV-MDA7/IL24-infected cells was 0.921±0.013, while those of the negative control-infected and untreated cells were 0.988±0.007 and 1.094±0.007, respectively (Fig. 3). Colony-forming ability of SMMC-7721 cells was analyzed by crystal violet staining, and the number of cells per colony significantly decreased after LV-MDA7/IL24 infection (P<0.05). Furthermore, we determined the number of colonies, and this number was found to decrease to 163±12 in samples overexpressing MDA7/IL24, compared with those
in the untreated and negative control-treated cells (180±8 and 201±8, respectively) (Fig. 4).

**MDA7/IL24 overexpression induces cell arrest and apoptosis.** To demonstrate the reasons why MDA7/IL24 overexpression results in reduced cell viability, apoptosis and cell cycle of MDA7/IL24 positive and negative HCC cells were examined by flow cytometry. The results showed that MDA7/IL24 overexpression induced cell apoptosis (Fig. 5A and B) and elevated the percentage of G1 phase cells in SMMC-7721 cells (Fig. 5C).

**MDA7/IL24 overexpression affects multiple cancer development pathways.** To explore the molecular mechanisms...
underlying the anticancer effects of MDA7/IL24, we performed microarray analysis and gene expression profiling in cells infected with either LV-MDA7/IL24 or the negative control. A significant difference in the expression levels between these cells was observed for 43 genes, 20 with upregulated and 23 with downregulated expression (Fig. 6A). KEGG pathway analysis demonstrated that these genes were significantly enriched in three pathways, including cell cycle regulation, DNA synthesis and transcriptional and apoptosis (Fig. 6B). Additionally, we verified the differential expression of several key molecules involved in these two pathways by western blotting, which showed that the upregulation of MDA7/IL24 induces the expression of caspase-3 and downregulates the expression of p-AKT, p-ERK1/2, CCNE2, and BCL2 (Figs. 7-10).

Discussion

Gene therapy has become a focus of current investigations aimed at improving HCC treatment (16). MDA7/IL24 is a member of the IL10 cytokine family, and was shown to induce apoptosis in different cancers specifically, including HCC (17), lung cancer (18), melanoma (19), breast cancer (20), pancreatic cancer (21), cervical cancer (22), and prostate cancer (23), but it does not affect normal cells (24). Therefore, this gene may represent an ideal gene therapy target (25). Additionally, MDA7/IL24 can induce the activation of immune system response aimed against cancer cells, and effectively inhibit neoplastic angiogenesis. It was demonstrated that the overexpression of this molecule
MA et al: MDA7/IL24 EXPRESSION INHIBITS HEPATOCELULAR CARCINOMA PROLIFERATION

and chemotherapy have synergistic effects (26). However, MDA7/IL24 overexpression mediated by lentiviruses has not been investigated previously.

Here, we constructed a LV-MDA7/IL24, and confirmed that the expression levels of this gene increase in SMMC-7721 cells infected with lentiviral particles carrying this vector. This demonstrated that the recombinant lentiviruses effectively promote the expression of MDA7/IL24 in HCC cells. MTT and colony formation assays demonstrated that lentivirus-mediated MDA7/IL24 expression markedly inhibits HCC cell proliferation. The number of cells and cell growth rate of LV-MDA7/IL24-infected cells were shown to be significantly decreased. In accordance with the results obtained in a previous study (27), we demonstrated the anticancer effects of MDA7/IL24.

However, the molecular mechanisms underlying the effects of MDA7/IL24 on HCC cells remain unclear. We performed gene expression profiling of SMMC-7721 cells infected with LV-MDA7/IL24, demonstrating that many genes show significantly different expression between MDA7/IL24-overexpressing cells and the control cells. We further performed functional pathway analysis, and several pathways involving the differentially expressed genes were found to be involved in cancer development (14), for example,
G1/S checkpoint and G2/M DNA damage signaling pathway. These pathways are crucial for cell cycle regulation, DNA synthesis, and transcription. Previously, it was reported that MDA7/IL24 induces IL20/IL22 receptor-independent apoptosis by modulating multiple apoptotic signaling pathways such as mitochondrial pathway, MAPK, PKR, GADD pathways, and others (28-30), and is involved in the accumulation of BAX and BCL2 (31). The results of our western blot analysis showed that MDA7/IL24 induces the expression of caspase-3 and inhibits the expression of p-AKT, p-ERK1/2, CCNE2, and BCL2.

CCNE2 and p-ERK1/2 are molecules involved in cell cycle regulation, which can induce tumor progression by regulating cell cycle transition. Cyclin E2 is a member of cyclin E family, which forms cyclin E-CDK2 complex with CDK2 (6). This complex promotes cell cycle progression by regulating G1/S phase transition, and the dysregulation of cyclin E2-CDK2 activity was shown to be involved in tumor development (32). Moreover, the overexpression of cyclin E2 was shown to be associated with poor survival of breast cancer patients (33). P-ERK1/2 is the activated form of ERK1/2, which plays an important role in cell proliferation by regulating cell cycle progression (34). P-ERK1/2 was demonstrated to be a HCC prognostic marker, since increased p-ERK1/2 levels correlate with a decrease in the overall survival (35). MDA7/IL24 overexpression induces CCNE2 and p-ERK1/2 downregulation, indicating that this molecule suppresses tumor progression by regulating cell cycle transition. Just as demonstrated by the experimental results, IL-24 overexpression induced G1 arrest in human HCC cells.

BCL2 is a 26-kDa oncoprotein, and its carcinogenic property is closely associated with the anti-apoptotic activity (36). As a regulator of apoptosis, BCL2 may promote tumor cell survival and inhibit apoptosis through the regulation of mitochondrial membrane permeability and the induction of tumor angiogenesis (37). BCL2 overexpression is related to tumor progression (38). P-AKT, an active form of AKT, plays an important role in the inhibition of tumor cell apoptosis, promoting tumor cell proliferation and angiogenesis (39). Many studies demonstrated that p-AKT is highly activated in many tumors, and its abnormal expression was shown to be closely related to tumor development and progression (40). Members of caspase family are key elements in the process of apoptosis, and their activation and abnormal expression can induce apoptosis through the interaction with other factors (41). Caspase-3 is the most important member of the caspase family involved in the process of apoptosis, mediating signaling triggered by many other molecules (42). In the present study, the expression levels of p-AKT, BCL2, and caspase-3 were shown to differ between the cells overexpressing MDA7/IL24 and the controls, indicating that MDA7/IL24 can inhibit tumor progression by inducing apoptosis, which is consistent with the results of cell functional experiments.

Taken together, our results demonstrate that MDA7/IL24 can inhibit the proliferation and suppress tumorigenicity of HCC cells in vitro. Furthermore, the MDA7/IL24 exerts its effects through the regulation of cell cycle transition and the induction of apoptosis. Therefore, we demonstrated that MDA7/IL24 has anticancer functions, its overexpression inhibits HCC progression, and it may represent a novel therapeutic target for cancer treatment.

Acknowledgements

The present study was supported by the National Natural Science Foundation of China Youth Fund (81201673). The manuscript was edited and proofread by Editage.

References

1. Wang CJ, Xiao CW, You TG, Zhang YX, Gao W, Zhou ZQ, Chen J, Xue XB, Fan J and Zhang H: Interferon-α enhances antitumor activities of oncolytic adenovirus-mediated IL-24 expression in hepatocellular carcinoma. Mol Cancer 11: 31, 2012.
2. Han B, Liu SH, Guo WD, Zhang B, Wang JP, Cao YK and Liu J: Notch1 downregulation combined with interleukin-24 inhibits invasion and migration of hepatocellular carcinoma cells. World J Gastroenterol 21: 9727-9735, 2015.
3. El-Serag HB, Marrero JA, Rudolph L and Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134: 1752-1763, 2008.
4. Li J, Shi L, Zhang X, Kang X, Wen Y, Qian H, Zhou Y, Xu W, Zhang Y, Wu M and Yin Z: Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo. Cancer Gene Ther 17: 271-279, 2010.
5. Xiao CW, Xue XB, Zhang H, Gao W, Yu Y, Chen K, Zheng JW and Wang CJ: Oncolytic adenovirus-mediated MDA-7/IL-24 overexpression enhances antitumor activity in hepatocellular carcinoma cell lines. Hepatobiliary Pancreat Dis Int 9: 615-621, 2010.
6. Huo W, Li ZM, Zhu YM, Bao YM and An LJ: MDA-7/IL-24 suppresses tumor adhesion and invasive potential in hepatocellular carcinoma cell lines. Oncol Rep 30: 986-992, 2013.
7. Jiang H, Lin JJ, Su ZZ, Goldstein NI and Fisher PB: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene 11: 2477-2486, 1995.
8. Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, Kang D, Jiang H, Lin JJ, Alexandre D, et al: Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppression and apoptosis inducing properties. Oncogene 20: 7051-7063, 2001.
9. Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broomelming L, Yekell S, Chada S and Grimm EA: Loss of MDA7 expression with progression of melanoma. J Clin Oncol 20: 1069-1074, 2002.
10. Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P and Fisher PB: Dual cancer specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 102: 14034-14039, 2005.
11. Caudell EG, Mummm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Ramesh R, Grimm EA: The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol 168: 6041-6046, 2002.
12. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR, Curiel DT and Dent P: mda7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: From the laboratory into the clinic. Cancer Biol Ther 2 (4 Suppl 1): S23-S27, 2003.
13. Tong AW, Nemunaitis J, Su D, Zhang Y, Cunningham C, Senzer N, Netto G, Rich D, Mhashilkar A, Parker K, et al: Intratumoral injection of ING4 241, a nonrelocating adenovector expressing the melanoma-differentiation associated gene-7 (mda7/IL-24): Biologic outcome in advanced cancer patients. Mol Ther 11: 160-172, 2005.
14. Lebedeva IV, Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Gupta P, Nemunaitis J, Cunningham C, Yacoub A, Dent P and Fisher PB: MDA7/IL-24: Exploiting cancer's Achilles' heel. Mol Ther 11: 4-18, 2005.
15. Song Z, Lin J, Sun Z, Ni J and Shu Y: RNAi-mediated downregulation of CDKL1 inhibits growth and colony-formation abilities and promotesapoptosis of human melanoma cells. J Dermatol Sci 79: 57-63, 2015.
16. Diao J, Wu C, Zhang J, Liu J, Zhang X, Hao P, Zhao S and Zhang Z: Loss of diacylglycerol kinase-Z inhibits cell proliferation and survival in human gliomas. Mol Neurobiol 35: 5425-5435, 2016.
17. Xue XB, Xiao CW, Zhang H, Lu AG, Guo W, Zhou QF, Guo XL, Zhong MA, Yang Y and Wang CJ: Oncolytic adenovirus GS600-IL24 selectively kills hepatocellular carcinoma cell lines. World J Gastroenterol 16: 4677-4684, 2010.
18. Wang X, Ye Z, Zhong J, Xiang J and Yang J: Adenovirus-mediated IL-24 expression suppresses hepatocellular carcinoma growth via induction of cell apoptosis and cyclin arrest and reduction of angiogenesis. Cancer Biother Radiopharm 22: 56-63, 2007.
19. Emdad L, Lebedeva IV, Su ZZ, Gupta P, Sarkar D, Settleman J and Fisher PB: Combinatorial treatment of non-small cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy. J Cell Physiol 210: 549-559, 2007.
20. Sarkar D, Su ZZ, Lebedeva IV, Sauane M, Gopalkrishnan RV, Valerie K, Dent P and Fisher PB: mda-7 (IL-24) mediates selective induction of cell cycle arrest and apoptosis in human melanoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 24: 585-596, 2005.
21. Shi H, Wei LL, Yuan CF, Yang JX, Yi FP, Ma YP and Song FZ: Melanoma differentiation-associated gene-7/interleukin-24 inhibits invasion and migration of human cervical cancer cells in vitro. Saudi Med J 11: 1671-1675, 2007.
22. Menezes ME, Shen XN, Das SK, Emdad L, Guo C, Yuan F, Li YJ, Archer MC, Zacksenhaus E, Windle JJ, et al.: MDA-7/IL-24 functions as a tumor suppressor gene in vivo in transgenic mouse models of breast cancer. Oncotarget 6: 36928-36942, 2015.
23. Saito Y, Miyahara R, Gopalban B, Litvak A, Inoue S, Shanker M, Branch CD, Mhashilkar AM, Roth JA, Chada S and Ramesh R: Selective induction of cell cycle arrest and apoptosis in human prostate cancer cells through adenoviral transfer of the melanoma differentiation associated-7 (mda-7)/interleukin-24 (IL-24) gene. Cancer Gene Ther 12: 238-247, 2005.
24. Kawabe S, Nishikawa T, Munshi A, Roth JA, Chada S and Meyn RE: Adenovirus-mediated mda-7 gene expression radiosensitizes non-small cell lung cancer cells via TP53-independent mechanisms. Mol Ther 6: 637-644, 2002.
25. Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, Pestka S and Fisher PB: MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev 14: 35-51, 2003.
26. Sauane M, Gopalkrishnan RV, Lebedeva I, Mei MX, Sarkar D, Su ZZ, Kang DC, Dent P, Pestka S and Fisher PB: Mda-7/IL-24 induces apoptosis of diverse cancer cell lines through JAK/STAT-independent pathways. J Cell Physiol 190: 334-345, 2002.
27. Su ZZ, Lebedeva IV, Sarkar D, Gopalkrishnan RV, Sauane M, Sigmon C, Yacoub A, Valerie K, Dent P and Fisher PB: Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner. Oncogene 22: 1164-1180, 2003.
28. Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S, Dent P, Reed JC and Fisher PB: Ionizing radiation enhances therapeutic activity of mda-7/IL-24: Overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene 25: 2339-2348, 2006.
29. Tahara I, Miyake K, Hanawa H, Kurai T, Hirayi I, Ishizaki M, Uchida E, Tajiri T and Shimada T: Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol Ther 15: 1805-1811, 2007.
30. Zhao Z, Liu J, Wang C, Wang Y, Jiang Y and Guo M: MicroRNA-25 regulates small cell lung cancer cell development and cell cycle through cyclin E2. Int J Clin Exp Pathol 7: 7726-7734, 2014.
31. Ye L, Guo L, He Z, Wang X, Lin C, Zhang X, Wu S, Bao Y, Yang Q, Song L and Lin H: Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. Oncotarget 17: 23767-23771, 2016.
32. Hwang HC and Clurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786, 2005.
33. Zhao S, Qiu ZX, Zhang L and Li WM: Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer. Tumor Biol 36: 4143-4150, 2015.
34. Li Q and Yang Z: Expression of phospho-ERK1/2 and P13-K in benign and malignant gallbladder lesions and its clinical and pathological correlations. J Exp Clin Cancer Res 28: 65, 2009.
35. Sabokrou A, Vaisi-Raygani A, Goodarzi MT, Khatami S, Taghizadeh-Jahed M, Shahabadi N, Lakpour N and Shakiba Y: Comparison between platinum-azidohydminde and azidohymidine effects on Bel-2 and telomerase gene expression in rats with hepatocellular carcinoma. Avicenna J Med Biotech 7: 50 -56, 2015.
36. Zhao N, Sun BC, Zhao XL, Wang Y, Meng J, Che N, Dong XY, Zhao S, Qiu ZX, Zhang L and Li WM: Expression of phospho-ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer. Cancer Gene Ther 12: 36928-36942, 2005.
37. Wu A, Li J, Yang X, Zhao W, Zhang Y, Li Q and Yang Z: Expression of phospho-ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer. Journal of Cancer Research 3: 36928-36942, 2005.
38. Fassan M, Nozato S, Iida H, Chen Y, Wang X, Kojima Y, Zhang X, Wu S, Ye L, Guo L, He Z, Wang X, Lin C, Zhang X, Wu S, Bao Y, Yang Q, Song L and Lin H: Upregulation of E2F8 promotes cell proliferation and tumorigenicity in breast cancer by modulating G1/S phase transition. Oncotarget 17: 23767-23771, 2016.
39. Hwang HC andClurman BE: Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786, 2005.